The ideas contest launched by Alfasigma at the beginning of November 2020 concluded the phase relating to the development and delivery of projects by the participants on January 6th. Alfathon collected over 300 entries from both individuals and teams.
3 challenges: from chemistry to software, from technologies to devices to support therapies. The award ceremony scheduled for 2021 at the Alfasigma Pomezia plant.
Three challenges to contribute to pharmaceutical research and innovation. Final prize of 5,000 euros for those who propose the best project. All projects will be evaluated for a further development.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.